Blockchain Registration Transaction Record

Lexaria Bioscience (NASDAQ: LEXX) Releases Q3, 2024 Financial Results and GLP-1 Study Program Roadmap

Lexaria Bioscience (NASDAQ: LEXX) announces Q3, 2024 financial results and updates on GLP-1 agonist research program, demonstrating commitment to health innovation.

Lexaria Bioscience (NASDAQ: LEXX) Releases Q3, 2024 Financial Results and GLP-1 Study Program Roadmap

This news matters as it showcases Lexaria's financial growth and its commitment to addressing significant health issues like diabetes and obesity, potentially impacting the lives of millions.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xef9b5c6e651e4fc171d73572429b874a83015d3cfc06059385ac1f4ea066e785
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprinticyV4wB-f908057610b0e1009e6ea2c963b297a1